



Aarey

DRUGS & PHARMACEUTICALS LTD.

MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICAL & SOLVENTS

GST No. : 27AAACA5253A1Z9
CIN No. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP, TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY : E-34, M.I.D.C, TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

Date:- 06th January, 2022

To,

BSE Limited The Manager, Corporate Service Department P.J. Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 524412	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: AAREYDRUGS
--	---

Sub : Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for quarter ended December, 2021.

Dear Sir/Madam,

We herewith enclose a Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company.

Please take on record of the same and oblige

Thanking You,

Yours faithfully,

For Aarey Drugs & Pharmaceuticals Ltd

M. S. Ghatalia

Mihir Ghatalia
Managing Director
DIN: 00581005



Encl.: a/a

To
The Company Secretary
Aarey Drugs & Pharmaceuticals Limited
202/3 Sahakar Bhavan
340/ 48 N N Street,
Mumbai-400009

Date: 5th January 2022

Subject : Confirmation Certificate in the matter of Regulation 74(5) of Securities and
Exchange Board of India (Depositories and Participants) Regulations, 2018.

Dear Sir,

In reference to the above captioned regulation, we hereby confirm that the securities received from the depository participants for dematerialisation during the quarter ended 31st December, 2021, were confirmed (accepted/rejected) to the depositories by us and that securities comprised in the said certificates have been listed on the stock exchanges where the earlier issued securities are listed.

SEBI vide its Circular No. SEBI/HO/MIRSD/RTAMB/P/CIR/2021/558 dated April 29, 2021 in view of the Covid-19 situation had provided relaxation in adherence to the prescribed timelines which included the processing of the demat requests by the Issuer Company/RTA. The relaxation was provided up to July 31, 2021. We have been informed that in view of the surge in volumes in Demat Requests, Update Requests, Investor correspondence etc. from July 2021 onwards, Registrars Association of India (RAIN) has requested SEBI for doubling the timelines for all activities with prescribed time limits for a limited period up to 31st March 2022. RAIN is yet to receive confirmation to the request from SEBI. We hereby also confirm that the security certificates received for dematerialisation have been confirmed/rejected and the security certificates received were mutilated and cancelled after due verification by the depository participant and the name of the depositories have been substituted in the register of members as the registered owner within 15 days. We request you to kindly take note of the above in your records.

Thanking You,

Yours faithfully,
For Link Intime India Pvt. Ltd



Balaji Sharma
Vice President- Corporate Registry